Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Repurchased
Ratios

Tonix Pharmaceuticals Holding (TNXP) Accumulated Depreciation & Amortization (2023 - 2025)

Tonix Pharmaceuticals Holding (TNXP) has 3 years of Accumulated Depreciation & Amortization data on record, last reported at $5.1 million in Q2 2025.

  • For Q2 2025, Accumulated Depreciation & Amortization rose 64.17% year-over-year to $5.1 million; the TTM value through Jun 2025 reached $5.1 million, up 64.17%, while the annual FY2024 figure was $4.1 million, 23.59% down from the prior year.
  • Accumulated Depreciation & Amortization reached $5.1 million in Q2 2025 per TNXP's latest filing, up from $4.1 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $6.3 million in Q1 2024 and bottomed at $2.5 million in Q1 2023.
  • Average Accumulated Depreciation & Amortization over 3 years is $4.2 million, with a median of $3.8 million recorded in 2024.
  • The widest YoY moves for Accumulated Depreciation & Amortization: up 148.78% in 2024, down 23.59% in 2024.
  • A 3-year view of Accumulated Depreciation & Amortization shows it stood at $5.4 million in 2023, then fell by 23.59% to $4.1 million in 2024, then grew by 23.82% to $5.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Depreciation & Amortization were $5.1 million in Q2 2025, $4.1 million in Q4 2024, and $3.6 million in Q3 2024.